Gain insight from entrepreneurs who’ve faced this challenge and innovated their way from lab to market. In each session of our new series, our innovators will share how they advanced their product or therapy from concept to clinical and commercial success. Join us to learn how they overcame the challenges of securing funding, clearing scientific roadblocks, and navigating the competitive biotech landscape to get started on the path to commercialization.
Bolden Therapeutics is a development stage biotechnology company developing compounds to treat serious neurological and neurodegenerative diseases. Their research focuses on pathological states such as Alzheimer’s disease, post traumatic stress disorder (PTSD) and treatment-resistant depression. Their innovative approach targets a novel signaling pathway that stimulates adult neurogenesis and demonstrates improved cognition in animal models.
Carol Malysz, Executive Director, RI Bio
Ed Hawrot, PhD, RI-INBRE/DRIVEN
Featured Bolden Therapeutics Speakers
Johnny Page, MS, Founding CEO
Justin Fallon, PhD, Scientific Co-Founder
Ashley Webb, PhD, Scientific Co-Founder
Charles Polsky, MD, Executive Chairman
Sudhir Agrawal, D.Phil, Business and Scientific Advisor